Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats

Hepatology

Volumn 34, Issue 4 I, 2001, Pages 745-750

  Yoshiji, Hitoshi ^a   Kuriyama, Shigeki ^a   Yoshii, Junichi ^a   Ikenaka, Yasuhide ^a   Noguchi, Ryuichi ^a   Nakatani, Toshiya ^a   Tsujinoue, Hirohisa ^a   Fukui, Hiroshi ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ACTIN; ANGIOTENSIN 2 RECEPTOR; CANDESARTAN; HYDROXYPROLINE; MESSENGER RNA; PERINDOPRIL; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; DRUG EFFECT; FIBROGENESIS; GENE EXPRESSION; LIVER FIBROSIS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STELLATE CELL;

EID: 0034802566     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2001.28231     Document Type: Article

References (43)

1. Endothelin induced contractility of stellate cells from normal and cirrhotic rat liver: Implications for regulation of portal pressure and resistance
2. Effect of angiotensin-II blockade on systemic and hepatic haemodynamics and on the renin-angiotensin-aldosterone system in cirrhosis with ascites
3. Role of angiotensin II in regulation of basal and sympathetically stimulated vascular tone in early and advanced cirrhosis
4. Molecular mechanisms of vascular renin-angiotensin system in myointimal hyperplasia
5. Angiotensin II receptors
6. The role of vasoactive mediators in portal hypertension
7. Differential response of normal and cirrhotic liver to vasoactive agents. A study in the isolated perfused rat liver
8. Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis
9. Angiotensin II induces contraction and proliferation of human hepatic stellate cells
10. Angiotensin II activates collagen I gene through a mechanism involving the MAP/ER kinase pathway
11. Angiotensin II is mitogenic for human lung fibroblasts via activation of the type 1 receptor
12. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells
13. Role of bradykinin-NO pathway in prevention of cardiac hypertrophy by ACE inhibitor in rat cardiomyocytes
14. Comparison of the antihypertensive effects of the new angiotensin II (AT1) receptor antagonist candesartan cilexetil (TCV-116) and the angiotensin converting enzyme inhibitor enalapril in rats
15. Interferon gamma treatment prevents procollagen gene expression without affecting transforming growth factor-beta 1 expression in pig serum-induced rat liver fibrosis in vivo
16. Herbal medicine Sho-saiko-to (TJ-9) prevents liver fibrosis and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet
17. KDR/Flk-1 is a major regulator of vascular endothelial growth factor- induced tumor development and angiogenesis in murine hepatocellular carcinoma cells
18. Tissue inhibitor of metalloproteinases-1 promotes liver fibrosis development in a transgenic mouse model
19. The prolyl 4-hydroxylase inhibitor HOE 077 prevents activation of Ito cells, reducing procollagen gene expression in rat liver fibrosis induced by choline-deficient L-amino acid-defined diet
20. Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis
21. Improved sandwich enzyme-linked immunosorbent assays for transforming growth factor beta 1
22. Suppressive effects of estradiol on dimethylnitrosamine-induced fibrosis of the liver in rats
23. The impact of interferon gamma receptor expression on the mechanism of escape from host immune surveillance in hepatocellular carcinoma
24. Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins
25. Trichostatin A modulates expression of p21wafl/cipl, Bcl-xL, ID1, ID2, ID3, CRAB2, GATA-2, hsp86 and TFIID/TAFII31 mRNA in human lung adenocarcinoma cells
26. Tissue inhibitors of metalloproteinases, hepatic stellate cells and liver fibrosis
27. Quantitation of a new potent angiotensin II receptor antagonist, TCV-116, and its metabolites in human serum and urine
28. Interspecies comparison of the metabolic pathways of perindopril, a new angiotensin-converting enzyme (ACE) inhibitor
29. The inhibitory effects of captopril on the growth of various cultured cells
30. Captopril reduces collagen and mast cell and eosinophil accumulation in pig serum-induced rat liver fibrosis
31. Biological functions of angiotensin and its receptors
32. Role of VEGF-fit receptor system in normal and tumor angiogenesis
33. Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells
34. Increased production of vascular endothelial growth factor (VEGF) by angiotensin II
35. Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor
36. Expression of vascular endothelial growth factor in normal liver and hepatocellular carcinoma: An immunohistochemical study
37. Hepatocellular hypoxia-induced vascular endothelial growth factor expression and angiogenesis in experimental biliary cirrhosis
38. Hypoxic stimulation of vascular endothelial growth factor expression in activated rat hepatic stellate cells
39. VEGF participates in neovascularization and sinusoidal capillarization in HCC
40. Inhibition of hepatic stellate cell proliferation and activation by the semisynthetic analogue of fumagillin TNP-470 in rats
41. The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: Possible role of the vascular endothelial growth factor
42. Activation-dependent contractility of rat hepatic lipocytes in culture and in vivo
43. (Latent) transforming growth factor beta in liver parenchymal cells, its injury-dependent release, and paracrine effects on rat hepatic stellate cells